Mamot et al. delivered chemotherapeutics, including DOX and vinorelbine, via modified cetuximab fragments targeting both wild-type EGFR and EGFRvIII, achieving up to 80% cell death in glioma cells within 15 min [416]. Here, EGFR is linked to central nervous system cancer.